CTF launched the Clinical Research Award (CRA) program in 2007, following the Foundation’s strategic planning meeting recommendation to accelerate NF Research. CRAs offer $150,000 each, to test a drug in a small group of patients or to develop clinical trial enabling tools (e.g. imaging, biomarkers,…). While $150,000 is a relatively small amount of funding for a clinical trial, CTF leverages our relationship with industry or larger funding organizations to provide drug at no cost to successful applicants.
Clinical Research Awards
NEUROFIBROMATOSIS CLINICAL RESEARCH AWARDS
2012 Funded Clinical Trial Awards
A Phase II Randomised Placebo-Controlled Double-Blind Cross-Over Trial of Methylphenidate in Children with Neurofibromatosis Type1 Dr. Kathryn North, The Children’s Hospital at Westmead
Effect of creating visual illness narratives on quality of life in children with Neurofibromatosis type 1: a pilot intervention study Dr. Nicole Ullrich, Boston Children's Hospital
Effect of anti-VEGF and radiation on NF2 vestibular Schwannoma Dr. Lei Xu, Massachusetts General Hospital
2011 Funded Clinical Trial Awards
Phase II Trial of Rapamycin - NF2 Tumors
Dr. Matthias Karajannis, New York University Langone Medical Center
New metrics for optic pathway glioma trials
Dr. Robert Avery, Children’s National Medical Center
Blood predictors of NF1 severity
Dr. Cynthia Hingtgen, Indiana University
Computerized ‘maze’ for NF1 learning disabilities trials
Dr. Nicole Ullrich, Children’s Hospital Boston
Responding to the evolving needs of NF research, The Clinical Research Awards program is intended to support early stage pilot clinical trials of candidate therapeutics or interventions for treatment of manifestations of NF1, NF2 and schwannomatosis. In addition, these awards are available to support innovative clinical trial enabling studies.
It is hoped that applications for Clinical Research Awards will be broad-thinking novel ideas. Examples of projects encouraged may include but are not limited to the following:
Preclinical/clinical collaborative studies. Note that all studies must include a clinical element – preclinical-only studies are not eligible
Applications to fund pilot clinical trials are welcomed and encouraged.
Clinical enabling studies such as biomarker and patient stratification that may better inform and help accelerate a clinical trial.
It is anticipated that CTF will fund up to three Clinical Research Awards of up to $150,000 (including overheads/indirect costs).
For CRA guidelines click here
To download patent policy click here
Application Process and Timeline:
LOI due: 7/15/13
LOI applicants notified: 8/5/13
Full applications due: 9/9/13
Applicants notified by: 10/15/13
Funding commences as soon as patent policy and award letter are signed.
Annette Bakker, email@example.com